Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages
Stefano Ugel, … , Susanna Mandruzzato, Vincenzo Bronte
Stefano Ugel, … , Susanna Mandruzzato, Vincenzo Bronte
Published September 1, 2015
Citation Information: J Clin Invest. 2015;125(9):3365-3376. https://doi.org/10.1172/JCI80006.
View: Text | PDF
Review Series Article has an altmetric score of 19

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

  • Text
  • PDF
Abstract

The generation of an inflammatory environment is favorable and often decisive for the growth of both primary tumors and metastases. Tumor cells either express membrane molecules or release tumor-derived soluble factors able to alter myelopoiesis. Tumor-reprogrammed myeloid cells not only create a tolerogenic environment by blocking T cell functions and proliferation, but also directly drive tumor growth by promoting cancer stemness, angiogenesis, stroma deposition, epithelial-to-mesenchymal transition, and metastasis formation. In this Review, we discuss the interplay between immunosuppressive and protumoral myeloid cells and detail their immune-regulatory mechanisms, the molecular pathways involved in their differentiation, as well as their potential role as prognostic and diagnostic biomarkers and prospective targets for innovative approaches to treat tumor-bearing hosts.

Authors

Stefano Ugel, Francesco De Sanctis, Susanna Mandruzzato, Vincenzo Bronte

×

Figure 1

Common phenotypic markers of MDSCs and TAMs.

Options: View larger image (or click on image) Download as PowerPoint
Common phenotypic markers of MDSCs and TAMs.
Several phenotypic markers ...
Several phenotypic markers of mouse and human MDSCs (A) and TAMs (B) have been identified (+ indicates expression, while – indicates lack of expression) and used to define specific cell subgroups, such as PMN-MDSCs, MO-MDSCs, and immature MDSCs (I-MDSCs), as well as M1-like and M2-like TAMs, by both cytofluorimetric and immunohistochemical analyses.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 1 news outlets
Referenced in 6 patents
Referenced in 2 Wikipedia pages
532 readers on Mendeley
See more details